Search results
Results from the WOW.Com Content Network
(Reuters) -FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca in the United States and certain other territories after the companies agreed to ...
When looking at the case of FibroGen’s (FGEN) roxadustat, the biotech’s therapy for sufferers of anemia related to chronic kidney disease (CKD), H.C. Wainwright’s Edwin Zhang thinks a repeat ...
No one likes being given the wrong information. Investors reacted in dismay and sent Fibrogen (FGEN) shares deep into the red following the company's embarrassing announcement. The biotech company ...
The stock of FibroGen (NAS:FGEN, 30-year Financials) is estimated to be possible value trap, according to GuruFocus Value calculation.
Roxadustat is reported to increase VEGF, a signal protein that can activate tumor growth [8] and also is considered to cause pulmonary hypertension. [9] In phase 3 trial conducted at 29 sites in China, roxadustat treatment was found to cause hyperkalemia, i.e., increase in serum potassium, and metabolic acidosis in patients.
One thing we could say about the analysts on FibroGen, Inc. ( NASDAQ:FGEN ) - they aren't optimistic, having just made... News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are ...
For premium support please call: 800-290-4726 more ways to reach us
FibroGen (FGEN) delivered earnings and revenue surprises of 13.33% and 1.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?